Britain’s competition watchdog alleged on Thursday that U.S. drugmaker Pfizer (PFE.N) and Flynn Pharma had breached competition law by ramping up the cost of an epilepsy drug used by more than 50,000 British patients. The Competition and Markets Authority (CMA) said its provisional view was that Pfizer and Flynn Pharma each abused a dominant position by charging “excessive and unfair” prices for phenytoin sodium capsules. Pfizer said it was cooperating fully with the CMA and noted a final decision on infringement had not yet been made.